Biosynth, a supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceuticals, is pleased to announce the next step in its custom peptide revolution.
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Lundbeck has commenced a Phase III trial to evaluate the safety and efficacy of the human monoclonal antibody in treating MSA. Credit: Copyright© 2025 H.